



cira

Center for Interdisciplinary Research on AIDS
at Yale University

World AIDS Day 2024 CIRA Talk: “Long-acting Injectable HIV PrEP: Current Research and Implications for Access”

Join us in a virtual CIRA Talk featuring a presentation followed by Q&A and discussion.



Onyema Ogbuagu
Yale School of Medicine
Speaker



Luke Davis
Yale School of Public Health
Moderator



E. Jennifer Edelman
Yale School of Medicine
Moderator

Tuesday, December 17, 2024

2:00 pm-3:00 pm ET

Register via Zoom:

<https://tinyurl.com/WAD2024CIRATalk>

Contact dini.harsono@yale.edu for questions about this event.

Organized by the Center for Interdisciplinary Research on AIDS (CIRA).
CIRA is supported by National Institute of Mental Health Grant No. P30MH062294,
Trace Kershaw, PhD, Principal Investigator.

World AIDS Day 2024 CIRA Talk: “Long-acting Injectable HIV PrEP: Current Research and Implications for Access”

**Tuesday, December 17, 2024
2:00 pm-3:00 pm ET**

OVERVIEW

Clinical trials on a novel long-acting injectable form of HIV pre-exposure prophylaxis (PrEP) are currently ongoing. Findings of a trial recently presented at the AIDS 2024 Conference have demonstrated the safety and efficacy of lenacapavir, a twice-yearly injectable drug, to prevent HIV among HIV-negative cisgender women (PURPOSE 1). An interim analysis of the sister study, PURPOSE 2, involving cisgender men, transgender men, transgender women, and gender non-binary individuals, reports a reduction of HIV infections by 96%.

The 2024 World AIDS Day theme is "Take the Rights Path" that promotes fostering inclusion of all communities and removing barriers to HIV prevention and care to end AIDS globally. This CIRA Talk features a presentation by Dr. Onyema Ogbuagu that will highlight current research on long-acting injectable HIV PrEP and a discussion on implications for access to promote HIV equity. Dr. Ogbuagu, Associate Professor of Medicine and Pharmacology at Yale School Medicine, is a practicing clinician and has served as principal investigator on multiple multinational trials for HIV treatment and prevention.

SPEAKER

Onyema Ogbuagu, MBBCh, FACP, FIDSA

Associate Professor of Medicine (AIDS) and of Pharmacology

Yale School of Medicine

Dr. Onyema Ogbuagu is an Associate Professor of Medicine and Pharmacology, and Director of the Yale Antivirals and Vaccines Research Program of the Yale AIDS Program, Section of Infectious Diseases of the Yale School of Medicine. His clinical responsibilities include educating and training medical students, residents and infectious diseases fellows in various capacities in inpatient and outpatient settings; and through structured course work and other teaching sessions. Furthermore, he has facilitated meaningful educational and research collaborations between faculty and trainees across institutions

Since 2017, he has been the Director of the Yale AIDS Program HIV clinical trials program, and a principal investigator on numerous pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds (HIV, SARS CoV-2). He is also a lead investigator on the international DISCOVER trial evaluating TAF/FTC vs TDF/FTC for HIV prevention among MSM and transgender women as well as PURPOSE-2 trial evaluating long acting lenacapavir for PrEP among MSM, transmasculinizing and transfeminizing individuals as well as gender non-binary individuals who have sex with men. He is also funded by NIAID (2023-25) for work advancing HIV PrEP for adolescent girls and young women in Liberia.

MODERATORS

Luke Davis, MD, MS

Associate Professor of Epidemiology (Microbial Diseases) and of Medicine (Pulmonary, Critical Care and Sleep Medicine)

Yale School of Public Health, Yale School of Medicine, CIRA

Luke Davis is a pulmonary and critical care physician and clinical epidemiologist using implementation science to find, treat, and prevent tuberculosis (TB) and HIV, two of the leading cause of death due to infection worldwide. He teaches and mentors students and directs a graduate program on implementation science at the Yale School of Public Health. He is also involved in several international research training programs focused on implementation science. He is a Yale Medicine physician, and attends in the Medical Intensive Care Unit and the Winchester TB Clinic at Yale-New Haven Hospital, caring for patients and their families and teaching medical students, residents, and fellows.

E. Jennifer Edelman, MD, MHS

Professor of Medicine (General Medicine)

Yale School of Medicine, CIRA

E. Jennifer Edelman, MD, MHS is a Professor of Medicine and Public Health. Certified as an internist, HIV specialist and in Addiction Medicine, she serves as an HIV provider and the physician consultant in the Addiction Medicine Treatment Program at the Yale-New Haven Hospital Nathan Smith HIV Clinic. Her research focuses on optimizing HIV prevention and treatment in the context of substance use, including opioid, alcohol and tobacco use. To this end and applying a range of methodologies, she leads and collaborates on NIH-funded projects to evaluate novel and implement evidence-based addiction treatment in medical settings, especially HIV treatment settings. In addition, her work has focused on understanding harms associated with opioid use among people with HIV. She collaborates with community-based and public health partners to promote HIV prevention, including use of pre-exposure prophylaxis (PrEP). She mentors trainees, including post-doctoral fellows and public health students, and is Associate Director of the Research on Addiction Medicine Scholars (RAMS) Program and co-Director of Education at the Yale Center for Clinical Investigation. She regularly serves on NIH grant review committees and is Associate Editor of Addiction Science and Clinical Practice.